...
AMGNMEGA

Amgen Inc.

HealthcareDrug Manufacturers - General
$388.16
$0.09(+2.33%)
52W$261.43
$390.09
FinancialsValuationvs ABBV
Updated Mar 1, 12:00 AM
RSI63
RS Rating80/99
Beta0.45
Volatility29%
F-Score7/9
Mkt Cap$209.2B
STAGE 2 UPTREND

Price Action

5Y Daily
50 DMA150 DMA200 DMA

Technical Summary

STAGE 2 UPTREND

Amgen Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 80), indicating clear outperformance against the broad market. Earnings growth of 111% provides fundamental context to the price action. Momentum will need to be maintained above the 50-day moving average to sustain this leadership phase.

Relative Strength
80
out of 99
Market Leader
Trend Score
4/4
Minervini Criteria
STAGE 2 UPTREND
Risk (Beta)
0.45
vs S&P 500
LOW VOL
52W Position
98%
from 52W low
Near High
Trend & Momentum Analysis

Trend Template (Minervini)

STAGE 2 UPTREND4/4 Criteria Met
CriterionValueStatus
Price > 50 SMA$348.14
50 SMA > 100 SMA$332.22
100 SMA > 150 SMA$317.30
150 SMA > 200 SMA$310.06

Price vs Moving Averages

PeriodValueSpreadSignal
20 SMA$370.04+4.90%ABOVE
50 SMA$348.14+11.50%ABOVE
100 SMA$332.22+16.84%ABOVE
150 SMA$317.30+22.33%ABOVE
200 SMA$310.06+25.19%ABOVE

Price Performance

1D+2.3%
1W+2.3%
1M+13.4%
3M+12.4%
6M+35.9%
YTD+18.5%
1Y+26.0%
3Y+18.8%
52-Week Trading Range98% from low
$388.16
52W Low$261.43
52W High$390.09

Technical Indicators

RSI (14)BULLISH
62.5
305070
VCP ScoreHOT
8/10
Base depth: 20.0%

Risk Profile

Beta
0.45
52W Vol
29%
ATR
$8.71
Max DD (1Y)
-20%

Volume Analysis

Today
388
50D Avg
2.26M
Vol Ratio
0.00x
Liquidity
VERY LIQUID

Earnings Momentum

Q1'25+1624%
$3.20
Q2'25+92%
$2.65
Q3'25+14%
$5.93
Q4'25+111%
$2.45
Fundamentals & Growth

Growth Trends

Compounded Sales Growth

10 Years:+5.43%
5 Years:+7.65%
3 Years:+11.77%
TTM:+9.92%

Compounded Profit Growth

10 Years:+4.62%
5 Years:+2.94%
3 Years:+5.52%
TTM:+88.48%

Stock Price CAGR

10 Years:+10.56%
5 Years:+11.32%
3 Years:+18.77%
1 Year:+26.00%

Return on Equity

10Y Avg:73.4%
5Y Avg:101.8%
3Y Avg:103.1%
Last Year:89.1%

Key Metrics

Market Cap$209.2B
Gross Margin82.5%
Net Margin21.0%
Piotroski F-Score7/9

More AMGN Analysis

Full Financial AnalysisDCF & Intrinsic ValueTotal Return Calculator

Compare With

AMGN vs ABBVABBVGILDNVOBIIB

Data Dictionary

RS Rating (Relative Strength)

Measures 12-month price performance vs all stocks. Rating of 80 meansAMGN outperformed 80% of all stocks. Scores >80 indicate market leaders.

Beta

Measures volatility vs S&P 500. Beta of 0.45 means 55% less volatile than market.

Piotroski F-Score

9-point financial strength score based on profitability, leverage, and efficiency. Score of 7/9. Scores 7-9 = strong, 4-6 average, 0-3 = weak.

VCP (Volatility Contraction Pattern)

Measures base formation quality. Higher scores indicate tighter consolidation near pivot points. Score of 8/10 with HOT status.

Frequently Asked Questions

Is AMGN in an uptrend right now?

AMGN has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, AMGN is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.

Is AMGN overbought or oversold?

AMGN's RSI (14) is 63. The stock is in neutral territory, neither overbought nor oversold.

Is AMGN outperforming the market?

AMGN has a Relative Strength (RS) Rating of 80 out of 99. Yes, AMGN is a market leader, outperforming 80% of all stocks over the past 12 months.

Where is AMGN in its 52-week range?

AMGN is trading at $388.16, which is 100% of its 52-week high ($390.09) and 98% above its 52-week low ($261.43).

How volatile is AMGN?

AMGN has a Beta of 0.45 and 52-week volatility of 29%. It's less volatile than the S&P 500 - generally more stable.